Good News: MS Drugs Taken During Breastfeeding May Not Impact Child DevelopmentEncouraging Findings from a Preliminary StudyMINNEAPOLIS, March 4, 2024 /PRNewswire/ -- A recent study suggests that certain monoclonal antibody medications used to treat multiple sclerosis MS may not pose a developmental risk to infants exposed to them through breastfeeding. The findings, presented at the American Academy of Neurologys Annual Meeting, offer reassurance to mothers with MS who may need to continue these therapies while nursing.Monoclonal Antibodies and MSMS is an autoimmune disorder that affects the central nervous system. In MS, the bodys immune system mistakenly attacks myelin, the protective coating around nerve fibers. Symptoms can range from fatigue and numbness to difficulty walking. Monoclonal antibodies are a type of medication that targets specific proteins involved in the immune system. They are used to treat a variety of conditions, including MS.Study Design and FindingsThe study, led by Dr. Kerstin Hellwig of Ruhr University in Germany, examined the health outcomes of 183 infants exposed to monoclonal antibodies through breastfeeding. These infants were compared to a control group of 183 infants whose mothers had MS but did not take monoclonal antibodies while breastfeeding. Researchers followed the infants for up to three years, assessing their health, development, and hospital stays. They found no significant differences between the two groups, suggesting that exposure to monoclonal antibodies through breastfeeding does not negatively impact child development.Limitations and ImplicationsWhile the study provides encouraging findings, it has limitations. Only about a third of the infants were followed for the full three years, making the results for the third year less conclusive. Despite these limitations, the study offers valuable insights into the potential risks and benefits of monoclonal antibody use during breastfeeding. For mothers with MS who are considering or currently taking these medications, the findings suggest that they may be able to continue breastfeeding without harming their childs development.ConclusionThe studys findings provide reassurance to mothers with MS who need to continue monoclonal antibody therapy while breastfeeding. However, further research is needed to these findings and assess the long-term effects of exposure to these medications through breastfeeding.